Back to News
Market Impact: 0.25

Dow Analyst Moves: MMM

MMMNDAQ
Analyst EstimatesAnalyst InsightsMarket Technicals & FlowsInvestor Sentiment & Positioning
Dow Analyst Moves: MMM

3M (MMM) is currently ranked as the 28th most favored stock among Dow Jones Industrial Average components and 451st within the S&P 500 by analysts. Despite these low analyst rankings, MMM's stock has posted a year-to-date gain of 10.2%, indicating a notable divergence between recent market performance and prevailing analyst sentiment.

Analysis

Analysis of 3M (MMM) reveals a significant divergence between prevailing analyst sentiment and recent stock performance. According to a tally of brokerage house opinions, MMM is ranked as the #28 pick out of 30 Dow Jones Industrial Average components and a lowly #451 within the S&P 500, indicating a strong bearish consensus among Wall Street analysts. Despite this negative positioning, the stock has registered a 10.2% year-to-date gain, suggesting that market momentum is currently overriding the professional outlook. This disconnect implies that investors are either pricing in a recovery or catalyst that analysts have not yet factored into their models, or that the current rally may lack broad institutional support, posing a potential risk.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

mixed

Sentiment Score

-0.15

Ticker Sentiment

MMM-0.10
NDAQ0.00

Key Decisions for Investors

  • Investors should investigate the fundamental reasons for the disconnect between MMM's 10.2% year-to-date gain and its low analyst rankings to determine if the market is pricing in a turnaround that analysts are overlooking.
  • Current holders of MMM should recognize the rally is occurring against a backdrop of weak institutional support, making it crucial to monitor for any change in analyst sentiment that could validate the price appreciation or signal a reversal.
  • For those considering a new position, the overwhelmingly poor analyst ratings should be treated as a material risk factor, warranting caution and a thorough review of the company's underlying health before committing capital.